Access cutting-edge thoracic neoplasms, lung diseases, small cell lung carcinoma treatment through this clinical trial at a research site in Fairfax. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Fairfax location
Preparing your pre-screening questions…
Access thoracic neoplasms, lung diseases, small cell lung carcinoma specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related thoracic neoplasms, lung diseases, small cell lung carcinoma treatment provided free
Check if you qualify for this thoracic neoplasms, lung diseases, small cell lung carcinoma clinical trial in Fairfax, VA
No-Cost Study Care
Local to Fairfax
Convenient for VA residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
This is a phase Ib/II, multicenter, open-label study of YL201 combined with atezolizumab. The study will include 2 parts. Part 1 of the study is a dose escalation in participants with previously untreated ES-SCLC to determine the safety and tolerability of YL201 in combination with fixed dose of atezolizumab. The planned dose levels of YL201 are 1.2 mg/kg, 1.6 mg/kg and 2.0 mg/kg. Part 2 consists of a dose optimization stage followed by a dose expansion stage. During the dose optimization stage, participants will be randomized 1:1:1 to receive either YL201 at 1.2 mg/kg,1.6 mg/kg or 2.0 mg/kg Q3W in combination with fixed dose of atezolizumab. The decision to initiate the dose expansion stage in Part 2 and choose one or two of the YL201 dose level(s) will be based on the review of safety, PK, and efficacy from the dose optimization stage. Treatment will continue until disease progression, unacceptable toxicity, or withdraw of consent.
Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
Yes, this clinical trial (NCT07407933) has an active research site in Fairfax, VA that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for thoracic neoplasms, lung diseases, small cell lung carcinoma treatment options in Fairfax, VA, this clinical trial (NCT07407933) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Fairfax research site is actively enrolling participants for this clinical trial. You'll receive care from experienced thoracic neoplasms, lung diseases, small cell lung carcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all thoracic neoplasms, lung diseases, small cell lung carcinoma clinical trials near you to find additional studies recruiting in your area.
See all lung cancer clinical trials recruiting in Fairfax — not just this study.
Browse Lung Cancer Trials in Fairfax →